2023 年第 8 期 第 18 卷

乌美溴铵维兰特罗吸入粉雾剂治疗支气管扩张症合并慢性阻塞性肺疾病的效果及对炎症因子水平的影响

Effect of umebronium veranterol inhalation powder on bronchiectasis complicated with chronic obstructive pulmonary disease and its influence on the level of inflammatory factors

作者：崔立静1安然2王亮1王彩彩1

英文作者：Cui Lijing1 An Ran2 Wang Liang1 Wang Caicai1

单位：1河北省胸科医院呼吸三科，石家庄050041；2河北省石家庄市第三人民医院老年医学二科，石家庄050011

英文单位：1Third Department of Respiratory Hebei Chest Hospital Shijiazhuang 050041 China; 2Second Department of Geriatrics the Third Hospital of Shijiazhuang Hebei Province Shijiazhuang 050011 China

关键词：支气管扩张症；慢性阻塞性肺疾病；乌美溴铵维兰特罗吸入粉雾剂；炎症反应

英文关键词：Bronchiectasis;Chronicobstructivepulmonarydisease;Umebroniumveranterolinhalationpowder;Inflammatoryreaction

• 摘要：

• 目的 探讨乌美溴铵维兰特罗吸入粉雾剂治疗支气管扩张症合并慢性阻塞性肺疾病（COPD）的效果及对炎症因子水平的影响。方法 选取2020年4月至2022年4月河北省胸科医院呼吸三科接诊的86例支气管扩张症合并COPD患者。完全随机分为对照组和观察组，每组43例。对照组在基础治疗基础上给予噻托溴铵粉吸入剂治疗，观察组在基础治疗基础上给予乌美溴铵维兰特罗吸入粉雾剂治疗，2组均治疗6个月。比较2组临床效果、6 min步行试验（6MWT）距离、COPD评估测试（CAT）评分、呼吸困难信念问卷（BBQ）评分、呼吸道阻力、炎症因子指标、不良反应总发生率。结果 观察组总有效率高于对照组［95.4%（41/43）比72.1%（31/43）］，差异有统计学意义（P<0.05）。治疗2、4、6个月后观察组6MWT距离长于对照组，CAT评分、BBQ评分、呼气阻力、吸气阻力及高敏C反应蛋白、白细胞介素8、白细胞介素6水平均低于对照组，差异均有统计学意义（均P＜0.05）。观察组与对照组不良反应总发生率差异无统计学意义［4.7%（2/43）比9.3%（4/43）］（P>0.05）。结论 乌美溴铵维兰特罗吸入粉雾剂可有效增强支气管扩张症合并COPD患者运动耐力，改善气短、咳痰等症状，降低呼吸道阻力，减轻炎症反应，且不良反应发生率相对较低。

• Objective To investigate the effect of umebronium veranterol inhalation powder on bronchiectasis complicated with chronic obstructive pulmonary disease(COPD) and its influence on the level of inflammatory factors. Methods  From April 2020 to April 2022, 86 patients with bronchiectasis complicated with COPD admitted to the Third Department of Respiratory, Hebei Chest Hospital were selected. They were randomly divided into control group and observation group, with 43 cases in each group. The control group was treated with tiotropium bromide powder inhaler on the basis of basic treatment, while the observation group was treated with umebronium veranterol inhalation powder on the basis of basic treatment. Both groups were treated for 6 months. The clinical effect, 6 min walk test (6MWT) distance, COPD assessment test(CAT) score, breathlessness beliefs questionnaire (BBQ) score, respiratory resistance, inflammatory factor index and total incidence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group［95.4% (41/43) vs 72.1% (31/43)］(P<0.05). After 2, 4, and 6 months of treatment, the 6MWT distance in the observation group was longer than that in the control group, and the CAT score, BBQ score, expiratory resistance, inspiratory resistance, and the levels of high-sensitivity C-reactive protein, interleukin-8 and interleukin-6 in the observation group were lower than those in the control group (all P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the observation group and the control group［4.7%(2/43) vs 9.3%(4/43)］(P>0.05). Conclusion ss  Umebronium veranterol inhalation powder can effectively enhance the exercise endurance of patients with bronchiectasis combined with COPD, improve the symptoms of shortness of breath and expectoration, and reduce respiratory resistance and inflammatory reaction, with a relatively low incidence of adverse reactions.